Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Net Cash Flow (2016 - 2025)

iBio (IBIO) has disclosed Net Cash Flow for 16 consecutive years, with $561000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 113.84% to $561000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $21.7 million, a 585.71% increase, with the full-year FY2025 number at -$5.6 million, down 182.22% from a year prior.
  • Net Cash Flow was $561000.0 for Q4 2025 at iBio, down from $19.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $19.5 million in Q3 2025 to a low of -$17.7 million in Q4 2021.
  • A 5-year average of -$3.1 million and a median of -$3.0 million in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: plummeted 478.32% in 2024, then surged 720.74% in 2025.
  • iBio's Net Cash Flow stood at -$17.7 million in 2021, then surged by 32.48% to -$11.9 million in 2022, then soared by 94.13% to -$701000.0 in 2023, then tumbled by 478.32% to -$4.1 million in 2024, then surged by 113.84% to $561000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Net Cash Flow are $561000.0 (Q4 2025), $19.5 million (Q3 2025), and $3.6 million (Q2 2025).